Dyne Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/05/24
Dyne Therapeutics Announces Pricing of $300 Million Public Offering of Common StockGlobeNewsWire • 01/05/24
Dyne Therapeutics stock gains, Sarepta falls after muscular dystrophy trial resultsMarket Watch • 01/03/24
Dyne Therapeutics Announces Positive Initial Clinical Data from ACHIEVE Trial in DM1 Patients and DELIVER Trial in DMD Patients Demonstrating Promise of the FORCE™ Platform in Developing Therapeutics for Rare Muscle DiseasesGlobeNewsWire • 01/03/24
Dyne Therapeutics to Host Virtual Event Tomorrow, January 3 at 8:00 AM ET, to Present Initial Clinical Data from ACHIEVE and DELIVER TrialsGlobeNewsWire • 01/02/24
Dyne Therapeutics Reports Third Quarter 2023 Financial Results and Provides Update on Significant Progress for ACHIEVE and DELIVER Trials and Upcoming Clinical MilestonesGlobeNewsWire • 10/30/23
Dyne Therapeutics Receives FDA Orphan Drug Designation for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1GlobeNewsWire • 09/20/23
Dyne Therapeutics to Present at Morgan Stanley 21st Annual Global Healthcare ConferenceGlobeNewsWire • 09/05/23
Dyne Therapeutics Reports Second Quarter 2023 Financial Results and Business HighlightsGlobeNewsWire • 08/03/23
Dyne Therapeutics Receives European Medicines Agency (EMA) Orphan Drug Designation for DYNE-101GlobeNewsWire • 05/25/23
Dyne Therapeutics' Preclinical Data Demonstrating FORCE™ Platform Delivery to CNS Featured in Oral Presentation at ASGCT Annual MeetingGlobeNewsWire • 05/17/23
Dyne Therapeutics Reports First Quarter 2023 Financial Results and Business HighlightsGlobeNewsWire • 05/11/23